• New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with ATRIPLA. In patients at risk for renal dysfunctio

First Page		Document Content
Date: 2015-01-27 17:10:16 Bristol-Myers Squibb Pharmacology Fixed dose combination Organofluorides Cyclopropanes Emtricitabine/tenofovir/efavirenz Tenofovir Efavirenz Emtricitabine Gilead Sciences Organic chemistry Chemistry		• New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with ATRIPLA. In patients at risk for renal dysfunctio Add to Reading List Source URL: www.gilead.com Download Document from Source Website File Size: 407,94 KB Share Document on Facebook

	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	Microsoft WordDOCX DocID: 1rnqZ - View Document
	Beilage 1: Arzneimittelmonographien DocID: 1rinj - View Document
	SAFETY DATA SHEET Page 1 of Total 6 Date of Issue: August 2016 SDS No. FMC/RAD/1 SECTION 1 DocID: 1rdYu - View Document
	imatinib and colon cancer. imatinib availability imatinib and cml imatinib and tight junction cancer imatinib prostate dercum and imatinib zactima plus imatinib DocID: 1rdbp - View Document